Advertisement

Tumor Biology

, Volume 37, Issue 1, pp 1309–1317 | Cite as

Identification of a panel of complex autoantigens (LGALS3, PHB2, MUC1, and GK2) in combination with CA15-3 for the diagnosis of early-stage breast cancer

  • Xiaoxiao Zuo
  • Ling Chen
  • Lifeng Liu
  • Zhe Zhang
  • Xiaojin Zhang
  • Qing Yu
  • Lu Feng
  • Xinhan Zhao
  • Tianjie Qin
Research Article

Abstract

Currently, there is no effective single antigen and there are only a very limited number of complex antigens for the diagnosis of early-stage breast cancer (BC). In this study, we used serological analysis of recombinant cDNA expression libraries (SEREX) in combination with phage display technology to screen complex autoantigens from the sera of BC patients. The cDNA expression library was constructed using tissue samples of three patients with BC at as early as stage T1N0M0. The serum samples of ten patients, including the three patients who provided tissue samples, as well as five healthy human subjects as controls were used to screen the library. All seven autoantigens were identified from the library by four rounds of screening and matched the existing genes after a blast search using NCBI-BLAST. Then, the expression conditions of the autoantibodies of the seven autoantigens and anti-CA15-3 in the sera from 100 BC patients and 50 healthy donors were examined by gray values. The data were analyzed by the area under the receiver operating characteristic (ROC) curve and logistic regression diagnostic models. In the end, a panel of complex autoantigens consisting of B11 (LGALS3), B18 (PHB2), B119 (MUC1), B130 (GK2), and CA15-3, which had a sensitivity of 87 % and a specificity of 76 %, were identified. The area under the curve (AUC) of the complex antigens was 0.872, which is significantly greater than that of anti-CA15-3 alone (AUC = 0.634) for the diagnosis of BC. Thus, this panel of complex antigens provides a promising strategy for the diagnosis of early-stage BC.

Keywords

Early-stage breast cancer SEREX Phage display technology Antigens 

References

  1. 1.
    Chourb S, Mackness BC, Farris LR, McDonald MJ. Improved detection of the MUC1 cancer antigen CA 15-3 by ALYGNSA fluorimmunoassay. Health. 2011;3:1949–4998.CrossRefGoogle Scholar
  2. 2.
    Misek DE, Kim EH. Protein biomarkers for the early detection of breast cancer. International journal of proteomics 2011, 2011.Google Scholar
  3. 3.
    Lumachi F, Basso SM, Brandes AA, Pagano D, Ermani M. Relationship between tumor markers CEA and CA 15-3, TNM staging, estrogen receptor rate and MIB-1 index in patients with pT1-2 breast cancer. Anticancer Res. 2004;24:3221–4.PubMedGoogle Scholar
  4. 4.
    Atahan K, Küpeli H, Gür S, Yiğitbaşı T, Baskın Y, Yiğit S, et al. The value of serum biomarkers (Bc1, Bc2, Bc3) in the diagnosis of early breast cancer. Int J Med Sci. 2011;8:148.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Dong X, Yang M, Sun H, Lu J, Zheng Z, Li Z, et al. Combined measurement of CA 15-3 with novel autoantibodies improves diagnostic accuracy for breast cancer. Onco Targets Ther. 2013;6:273–9.PubMedPubMedCentralGoogle Scholar
  6. 6.
    Wang Y, Balan V, Gao X, Reddy PG, Kho D, Tait L, et al. The significance of galectin-3 as a new basal cell marker in prostate cancer. Cell Death Dis. 2013;4:e753.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Balan V, Wang Y, Nangia-Makker P, Kho D, Bajaj M, Smith D, et al. Galectin-3: a possible complementary marker to the PSA blood test. Oncotarget. 2013;4:542–9.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Al-Salam S, Al-Salam M, Al AM. Galectin-3: a novel protein in cerebellar hemangioblastoma. Int J Clin Exp Pathol. 2013;6:853–61.PubMedPubMedCentralGoogle Scholar
  9. 9.
    Righi A, Morandi L, Leonardi E, Farnedi A, Marucci G, Sisto A, et al. Galectin-3 expression in pituitary adenomas as a marker of aggressive behavior. Hum Pathol. 2013;44:2400–9.CrossRefPubMedGoogle Scholar
  10. 10.
    Dawson H, Andre S, Karamitopoulou E, Zlobec I, Gabius HJ. The growing galectin network in colon cancer and clinical relevance of cytoplasmic galectin-3 reactivity. Anticancer Res. 2013;33:3053–9.PubMedGoogle Scholar
  11. 11.
    Mazurek N, Byrd JC, Sun Y, Ueno S, Bresalier RS. A galectin-3 sequence polymorphism confers TRAIL sensitivity to human breast cancer cells. Cancer. 2011;117:4375–80.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Lee MH, Lin L, Equilibrina I, Uchiyama S, Matsunaga S, Fukui K. ASURA (PHB2) is required for kinetochore assembly and subsequent chromosome congression. Acta Histochem Cytochem. 2011;44:247–58.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Sievers C, Billig G, Gottschalk K, Rudel T. Prohibitins are required for cancer cell proliferation and adhesion. PLoS ONE. 2010;5:e12735.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Zhang Y, Wang Y, Xiang Y, Lee W, Zhang Y. Prohibitins are involved in protease-activated receptor 1-mediated platelet aggregation. J Thromb Haemost. 2012;10:411–8.CrossRefPubMedGoogle Scholar
  15. 15.
    Cheng J, Gao F, Chen X, Wu J, Xing C, Lv Z, Xu W, Xie Q, Wu L, Ye S, Xie H, Zheng S, Zhou L. Prohibitin-2 promotes hepatocellular carcinoma malignancy progression in hypoxia based on a label-free quantitative proteomics strategy. MolCarcinog 2013.Google Scholar
  16. 16.
    Jager D, Filonenko V, Gout I, Frosina D, Eastlake-Wade S, Castelli S, et al. NY-BR-1 is a differentiation antigen of the mammary gland. Appl Immunohistochem Mol Morphol. 2007;15:77–83.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Xiaoxiao Zuo
    • 1
  • Ling Chen
    • 1
  • Lifeng Liu
    • 1
  • Zhe Zhang
    • 2
  • Xiaojin Zhang
    • 1
  • Qing Yu
    • 1
  • Lu Feng
    • 1
  • Xinhan Zhao
    • 1
  • Tianjie Qin
    • 1
  1. 1.Department of OncologyFirst Affiliated Hospital of Xi’an Jiaotong University Medical CollegeXi’anPeople’s Republic of China
  2. 2.Department of Traditional Chinese MedicineFirst Affiliated Hospital of Xi’an Jiaotong University Medical CollegeXi’anPeople’s Republic of China

Personalised recommendations